FDA Detox Medications & Clinical Research Encyclopedia
Official US Food & Drug Administration (FDA) monographs, PubChem chemical pharmacology profiles, and active ClinicalTrials.gov research studies for addiction recovery and 24/7 medical detox.
FDA-Approved MAT & Detox Medications
Buprenorphine / Naloxone
Maintenance treatment of opioid dependence as part of a complete treatment plan including counseling and psychosocial support.
Methadone Hydrochloride
Detoxification treatment of opioid addiction and maintenance treatment of opioid dependence in certified Opioid Treatment Programs (OTP).
Naltrexone Extended-Release
Prevention of relapse to opioid dependence following opioid detoxification, and treatment of alcohol dependence.
Naloxone Hydrochloride
Emergency treatment of known or suspected opioid overdose, manifested by respiratory and/or central nervous system depression.
Acamprosate Calcium
Maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
Disulfiram
Aid in the management of selected recovery patients who want to remain in a state of enforced sobriety from alcohol.
MAT & Detox Centers Geo-Map
FDA-Approved Medication Assisted Treatment (MAT) Centers
Balanced 50-State coverage with municipal pin markers across all US regions
Active US Clinical Research Trials (ClinicalTrials.gov APIv2)
Live interventional studies currently recruiting patients for addiction and detox research
Successful Transitions and Reintegration Tools for Veterans (START-VETS)
This study will develop prison reentry materials for Veterans leaving prison.
Comprehensive HIV and Harm Prevention Via Telehealth
The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat
The overall objective of this study it to use Positron Emission Tomography (PET) brain imaging and a radiotracer that measures the epigenetic marker Histone Deacetylase 6 (HDAC6) to examine HDAC6 expression in people with Post-Traumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD), or concurrent PTSD and AUD with control groups. While there are a large number of studies conducted in preclinical stress and addiction models, these findings have not been translated to people living with these disorders. This study will examine relationships between HDAC6 and clinical variables of interest. Findings could direct treatment development.
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use
The goal of this clinical trial is to learn if buprenorphine can be started for opioid use disorder with fentanyl use without requiring or precipitating opioid withdrawal. To be eligible, participants must have moderate or severe opioid use disorder and must have fentanyl detected on a urine drug test. Participants will be admitted to a monitored research unit for the trial. They will be randomized to start buprenorphine with either standard initiation or with a new approach called rapid outpatient low-dose initiation (ROLDI). For standard initiation, participants will be instructed to arrive to the unit with at least 8 hours since last fentanyl use. Once they have at least moderately severe opioid withdrawal (Clinical Opiate Withdrawal Scale \[COWS\] 11 or higher), participants will receive 2 mg, 2 mg, 4 mg, and then 8 mg sublingual buprenorphine, with doses every 2 hours. They will then continue 8 mg twice daily (or up to three times daily). This is the current standard of care. For ROLDI, participants will not be required to have a period abstinence, they will have no or minimal withdrawal (COWS 4 or less) when starting buprenorphine, and participants will take 0.5, 0.5, 0.5, 0.5, 2, 16 mg with doses scheduled every 2 hours. They will then continue 8mg twice daily (or up to three times daily). The main aim of this clinical trial is to assess whether ROLDI is safe, feasible, acceptable to patients, and worthwhile to study in a larger trial. The secondary aim is to describe fentanyl and norfentanyl pharmacokinetics (that is to say, fentanyl and norfentanyl concentration in blood and urine) during early abstinence to understand why some people using fentanyl develop precipitated withdrawal with standard initiation.
Treatment Facilities by US State
Select any state on the interactive map or explore top destination hubs to view verified SAMHSA facility listings.
Top Destination Treatment Hubs
6 Premier RegionsCalifornia
Coastal detox & luxury retreats
Florida
Palm Beach & South FL recovery sanctuaries
Texas
Houston & Austin residential rehabs
New York
Metropolitan & upstate medical detox
Colorado
Mountain retreat & holistic wellness
Arizona
Desert sanctuary & dual diagnosis